Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Neurology · HIV-Associated Neurocognitive Disorder

Testing and Getting a Diagnosis

At a Glance

HAND is diagnosed through more than a brief memory screen: clinicians combine medical history, comprehensive cognitive testing, daily-function assessment, and evaluation for other causes. MRI or lumbar puncture is considered when symptoms progress quickly or another problem is suspected.

Diagnosing HIV-Associated Neurocognitive Disorder (HAND) is a process of discovery. It is a clinical diagnosis based on your medical history, your performance on cognitive tests, an assessment of your daily functioning, and a careful evaluation of alternative causes [1][2].

Screeners vs. Full Evaluation

You may have taken a brief 10-minute test in your doctor’s office, such as the MoCA (Montreal Cognitive Assessment) or the IHDS (International HIV Dementia Scale). While these are helpful “screeners” to see who might need more testing, they are not enough for a formal diagnosis [3].

  • Screeners can miss milder impairment and can sometimes produce abnormal results for reasons completely unrelated to HAND [4][5]. No single screener cutoff establishes a HAND diagnosis.

The Deep Dive: Comprehensive Testing

A comprehensive neuropsychological evaluation is preferred, especially when the diagnosis is uncertain [2][6]. This is a series of standardized tests—often taking several hours—that measure different “domains” or ways your brain works. A full evaluation typically checks:

  • Processing Speed: How quickly you can take in and react to information [7].
  • Attention and Working Memory: Your ability to focus and hold information in your mind, like a phone number you just heard [8].
  • Executive Function: Your ability to plan, organize, and solve complex problems [8].
  • Learning and Memory: How well you learn new information and recall it later [8].
  • Fine Motor Skills: How well you can coordinate small movements, such as with your fingers [7].

Why “Normative Data” Matters

One of the most important parts of objective cognitive testing is how your scores are interpreted. Your results are compared to normative data—the scores of a large group of people who are similar to you in age, education level, and cultural background [2][7].

This adjustment is crucial because a 70-year-old with a high school diploma is expected to have different scores than a 30-year-old with a PhD. Without these adjustments, people can be easily misdiagnosed [9][10]. If you feel the tests don’t reflect your background or language, it is important to tell your doctor [11].

The Role of Daily Function

To determine which type of HAND a person has, doctors perform a functional assessment. They look at whether cognitive changes are impacting your “Instrumental Activities of Daily Living” (IADLs) [12].

  • ANI (Asymptomatic): You have low test scores across at least two domains, but your daily life is unaffected [13].
  • MND (Mild): You have mild trouble with complex tasks like managing finances or medications [14].
  • HAD (Dementia): You have significant difficulty managing daily life and may need help from others [14].

Imaging and Spinal Fluid

An MRI or a lumbar puncture (spinal tap) is not routinely required for stable, mild cognitive complaints. However, if your symptoms are progressing quickly, or your clinician suspects an infection or CSF viral escape (where the virus is active in the spinal fluid), they will direct you to get an MRI to look at the brain’s structure or a lumbar puncture to check the CSF [15][16][17]. These tools help ensure that other conditions, like infections or vascular issues, are not being missed [1]. It is important to note that even if HIV RNA is detected in the CSF, it is not automatically the sole cause of your symptoms.

Common questions in this guide

How is HAND diagnosed?
HAND is diagnosed using your medical history, cognitive test results, and an assessment of how thinking changes affect everyday activities. A clinician also looks for other explanations, such as mood or sleep problems, infections, or vascular issues, rather than relying on one test.
Can a MoCA or IHDS score confirm HAND?
No. The MoCA and IHDS are brief screening tools that can show whether more evaluation may be needed, but no single screening score establishes a HAND diagnosis. These screeners can miss mild impairment or be abnormal for reasons unrelated to HAND.
What happens during a full cognitive evaluation for HAND?
A comprehensive neuropsychological evaluation uses standardized tests and may take several hours. It measures processing speed, attention and working memory, planning and problem-solving, learning and memory, and fine motor skills. Results are interpreted alongside your medical history and daily functioning.
Why do age, education, and cultural background matter in cognitive testing?
Test scores are compared with results from people with similar age, education, and cultural backgrounds. This helps clinicians distinguish a true cognitive change from a score influenced by differences in schooling, language, or cultural experience. Tell your clinician if the tests do not reflect your language or background.
How does daily functioning affect a HAND diagnosis?
Clinicians assess whether cognitive changes interfere with complex everyday activities such as managing money or medications. Low scores without an effect on daily life may fit asymptomatic neurocognitive impairment, while increasing difficulty with daily tasks may fit mild neurocognitive disorder or HIV-associated dementia. The classification uses daily functioning as well as test results.
When might I need an MRI or lumbar puncture for HAND?
These tests are not routinely needed for stable, mild cognitive complaints. A clinician may recommend a brain MRI or lumbar puncture when symptoms progress quickly or when an infection, vascular problem, or HIV activity in spinal fluid is suspected. Finding HIV RNA in spinal fluid does not automatically prove it is the only cause of symptoms.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Dementia associated with AIDS.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which cognitive domains—like processing speed or executive function—will the tests cover, and how long should I expect the evaluation to take?
  2. 2.What specific normative data will you use to adjust my scores for my age, education level, and cultural background?
  3. 3.If my test scores are low but I feel I am managing my daily life well, how will that affect my diagnosis?
  4. 4.Is there a clinical reason to perform an MRI or a lumbar puncture right now, or should we wait for the results of other assessments?
  5. 5.How often should we repeat these tests to see if my cognitive health is stable or changing over time?

References

References (17)
  1. 1

    One for all, all for one: neuro-HIV multidisciplinary platform for the assessment and management of neurocognitive complaints in people living with HIV.

    Damas J, Darling KEA, Bidlingmeyer P, et al.

    HIV medicine 2023; (24(6)):738-748 doi:10.1111/hiv.13472.

    PMID: 36890672
  2. 2

    Multimodal Approach to Neurocognitive Function in People Living with HIV in the cART Era: A Comprehensive Review.

    Moschopoulos CD, Stanitsa E, Protopapas K, et al.

    Life (Basel, Switzerland) 2024; (14(4)) doi:10.3390/life14040508.

    PMID: 38672778
  3. 3

    Validity of the Montreal Cognitive Assessment and the HIV Dementia Scale in the assessment of cognitive impairment in HIV-1 infected patients.

    Janssen MA, Bosch M, Koopmans PP, Kessels RP

    Journal of neurovirology 2015; (21(4)):383-90 doi:10.1007/s13365-015-0324-4.

    PMID: 25678141
  4. 4

    Utility of Using the Montreal Cognitive Assessment (MoCA) as a Screening Tool for HIV-Associated Neurocognitive Disorders (HAND) In Multi-Ethnic Malaysia.

    Mukherjee T, Sakthivel R, Fong HY, et al.

    AIDS and behavior 2018; (22(10)):3226-3233 doi:10.1007/s10461-018-2073-x.

    PMID: 29508103
  5. 5

    A Comparison of Five Brief Screening Tools for HIV-Associated Neurocognitive Disorders in the USA and South Africa.

    Joska JA, Witten J, Thomas KG, et al.

    AIDS and behavior 2016; (20(8)):1621-31 doi:10.1007/s10461-016-1316-y.

    PMID: 26860536
  6. 6

    Validity of Digital Assessments in Screening for HIV-Related Cognitive Impairment: a Review.

    Wilson S, Milanini B, Javandel S, et al.

    Current HIV/AIDS reports 2021; (18(6)):581-592 doi:10.1007/s11904-021-00585-8.

    PMID: 34820750
  7. 7

    Neuropsychological tests associated with symptomatic HIV-associated neurocognitive disorder (HAND) in a cohort of older adults in Tanzania.

    Fotheringham L, Lawson RA, Urasa S, et al.

    Journal of the International Neuropsychological Society : JINS 2024; (30(7)):660-670 doi:10.1017/S1355617724000201.

    PMID: 38766814
  8. 8

    Neurocognitive impairment in treatment-experienced adults living with HIV attending primary care clinics in Zimbabwe.

    Nyamayaro P, Gouse H, Hakim J, et al.

    BMC infectious diseases 2020; (20(1)):383 doi:10.1186/s12879-020-05090-8.

    PMID: 32471350
  9. 9

    The Montreal Cognitive Assessment-Basic (MoCA-B) is not a reliable screening tool for cognitive decline in HIV patients receiving combination antiretroviral therapy in rural South Africa.

    Hakkers CS, Beunders AJM, Ensing MHM, et al.

    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2018; (67()):36-40 doi:10.1016/j.ijid.2017.11.024.

    PMID: 29183843
  10. 10

    Sex differences in HIV-associated cognitive impairment.

    Sundermann EE, Heaton RK, Pasipanodya E, et al.

    AIDS (London, England) 2018; (32(18)):2719-2726 doi:10.1097/QAD.0000000000002012.

    PMID: 30407251
  11. 11

    Development of a neurocognitive test battery for HIV-associated neurocognitive disorder (HAND) screening: suggested solutions for resource-limited clinical settings.

    Chan LG, Ho MJ, Lin YC, et al.

    AIDS research and therapy 2019; (16(1)):9 doi:10.1186/s12981-019-0224-4.

    PMID: 30987670
  12. 12

    Two-year clinical trial examining the effects of speed of processing training on everyday functioning in adults with human immunodeficiency virus-associated neurocognitive disorder (HAND) and borderline HAND in the U.S. Deep South: Findings of the Think Fast Study.

    Vance DE, Fazeli PL, Azuero A, et al.

    Applied neuropsychology. Adult 2025; (32(3)):747-760 doi:10.1080/23279095.2023.2209900.

    PMID: 37200482
  13. 13

    Cognitive Intra-individual Variability in HIV: an Integrative Review.

    Vance DE, Del Bene VA, Frank JS, et al.

    Neuropsychology review 2022; (32(4)):855-876 doi:10.1007/s11065-021-09528-x.

    PMID: 34826006
  14. 14

    Changing clinical phenotypes of HIV-associated neurocognitive disorders.

    Sacktor N

    Journal of neurovirology 2018; (24(2)):141-145 doi:10.1007/s13365-017-0556-6.

    PMID: 28752495
  15. 15

    Managing cognitive impairment in people with HIV.

    Alford K, O'Brien C, Banerjee S, et al.

    Current opinion in infectious diseases 2025; (38(1)):1-9 doi:10.1097/QCO.0000000000001078.

    PMID: 39602088
  16. 16

    Dual antiretroviral therapies are effective and safe regimens in the central nervous system of neurologically symptomatic people living with HIV.

    Trunfio M, Rugge W, Mighetto L, et al.

    AIDS (London, England) 2020; (34(13)):1899-1906 doi:10.1097/QAD.0000000000002601.

    PMID: 32701580
  17. 17

    HIV Cerebrospinal Fluid Escape: Interventions for the Management, Current Evidence and Future Perspectives.

    Kelly SH, Nightingale S, Gupta RK, Collier DA

    Tropical medicine and infectious disease 2025; (10(2)) doi:10.3390/tropicalmed10020045.

    PMID: 39998049

This page explains how clinicians evaluate HIV-associated neurocognitive disorder for informational purposes only and does not constitute medical advice. Your HIV clinician and neuropsychology team should interpret your test results and decide whether imaging or a lumbar puncture is appropriate.